Diogo Pinto,  —

CENTOGENE and Denali Therapeutics are teaming up to identify and recruit Parkinson’s disease patients who carry mutations in the LRRK2 gene for future clinical trials, the companies announced. CENTOGENE will carry out a targeted global recruitment campaign to identify and characterize Parkinson’s patients with LRRK2…

The Parkinson’s Disease News Today forums are a place to connect with other patients, share tips and talk about the latest research. Check…

Patients diagnosed with Parkinson’s disease dementia (PDD) and dementia with Lewy bodies (DLB) were found to have a mortality rate more than three times higher than the general population, according to researchers in Sweden. The 10-year follow-up study, titled “Relative survival in patients with dementia with Lewy bodies…

Alpha-synuclein (aSyn), a protein linked to Parkinson’s disease and dementia with Lewy bodies (DLB), exerts its harmful effects by disrupting the normal function of protein production, a study has found. This sheds light on the involvement of the aSyn protein in Parkinson’s disease, confirming its potential as a…

The Michael J. Fox Foundation is continuing to support the advancement of Parkinson’s disease research by investing up to $7.5 million in projects proposed by investigators, the nonprofit recently announced. Funding will be considered for projects aimed at the following four areas: exploring new biological targets for therapeutic development;…

Insulin resistance, a condition in which cells fail to respond normally to the hormone insulin, affects almost two-thirds of non-diabetic Parkinson’s patients despite normal blood sugar levels, according to a study. This finding suggests that insulin resistance may be a common undetected condition in Parkinson’s disease, especially in patients who are…

Denali Therapeutics’ reports that its investigational compound for Parkinson’s disease, DNL201, was found to be safe and well-tolerated by healthy individuals in a Phase 1 clinical trial. The company is planning to advance the compound into a Phase 1b study in patients, a press release states. DNL201 is an inhibitor…

A multidisciplinary research team at Purdue University in Indiana and the University of Bordeaux in France was awarded a $107,000 grant by the The Michael J. Fox Foundation for Parkinson’s Research to study the neuroprotective ability of a newly discovered gene associated with Parkinson’s disease. The gene was discovered by Jean-Christophe Rochet, PhD, a…